Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: Perspectives from Germany

Journal of Epidemiology and Community Health

Volumn 64, Issue 2, 2010, Pages 103-104

  Döran, Martina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER; DISEASE CONTROL; DISEASE INCIDENCE; IMMUNE SYSTEM; VACCINATION; WOMENS HEALTH;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; GERMANY; HEALTH CARE QUALITY; HUMAN; PAPILLOMAVIRUS INFECTION; STANDARD; UTERINE CERVIX TUMOR; UTILIZATION REVIEW; VAGINA SMEAR;

ADOLESCENT; ADULT; AGED; FEMALE; GERMANY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROCESS ASSESSMENT (HEALTH CARE); UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 75249092978     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2008.086959     Document Type: Article

References (16)

1. FDA. Vaccines and Related Biological Products Advisory Committee (VRBPAC) background document, May 2006. http://www.fda.gov/ohrms/dockets/ac/06/brieflng/ 2006-4222B3.pdf (accessed 26 Nov 2009).
2. International Agency of Research Against Cancer. World cancer report 2008. Boyle P, Levin B, eds. Lyon: IARC Press, 2008, p. 418.
3. FDA. Vaccines and Related Biological Products Advisory Committee (VRBPAC) background Document, May 2006. http://www.fda.gov/ohrms/dockets/ac/06/brieflng/ 2006-4222B3.pdf (Page 17, Table 25, 10th column) (accessed 26 Nov 2009).
4. Gerhardus A, Düren M, Gerlach FM, et al. Gebärmutterhalskrebs. Wie wirksam ist die HPV-lmpfung? [Cervical cancer. How effective is HPV vaccination?] Dtsch Arztebl 2009;106:A330-4. http://www.aerzteblatt.de/v4/ archiv/artlkel.asp?src=suche&p=gerhardus&ld=63448 (accessed 26 Nov 2009).
5. Brown DR, Kjaer SK, Slgurdsson K, et al. The Impact of quadrivalent human papillomavirus (HPV; types 6,11,16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvacine HPV types In generally HPV-naïve women aged 16-26 years. J Infect Dis 2009;199: 926-935
6. Lippman A. Human papillomavirus (HPV) vaccination and the development of public policies. J Epidemiol Community Health 2008;62: 570-571
7. International Agency of Research against Cancer. World cancer report 2003. Boyle P, Levin B, eds. Lyon: IARC Press, 2003.
8. Schenck U, von Karsa L. Cervical cancer screening in Germany. Eur J Cancer 2000;36: 2221-2226
9. 9. Becker N. Epidemiological aspects of cancer screening In Germany. J Cancer Res Clin Oncol 2003;129: 691-702. (Pubitemid 38002300)
10. Rückinger S, Tauscher M, Redel R, et al. Teilnahme an Früherkennungsuntersuchungen für Zervixkarzlnom nach Alter und Region: Eine Kohortenstudie mit 2 223 135 Frauen In Bayern. [Participation In cervical cancer screening by age and region-a cohort study with a 3 1/2 year follow-up on 2,223,135 women In Bavaria]. Gesundheitswesen 2008;70:e17-21.
11. Rückinger S, von Kries R, Pauli S, et al. Die Krebsfrü herkennungsuntersuchung für Frauen wird In Regionen mit niedrigerem Haushaltseinkommen seltener in Anspruch genommen-Analyse von Daten der Kassenärztlichen Vereinigung Bayerns. [Cancer Screening for women is less frequently visited in regions with lower household Income-analysis of data from health insurances In Bavaria]. Gesundheitswesen 2008;70: 393-397
12. Seidel D, Becker N, Rohrmann S, Nimptsch K, et al. Socio-demographic characteristics of participation In the opportunistic German cervical cancer screening programme: results from the EPIC-Heldelberg cohort. J Cancer Res Clin Oncol 2009;135: 533-541
13. Wentzensen N, Klug SJ. Früherkennung des Zervlxkarzinoms: Suche nach einem Gesamtkonzept. [Early detection of cervical carcinomas-finding an overall approach]. Dtsch Arztebl lit 2008;105: 617-622 http://www.aerzteblatt.de/int/ artlcle.asp?ld=61517 (accessed 26 Nov 2009).
14. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years In Germany: results for 8 466 patients. Br J Cancer 2003;88: 1570-1577
15. Schneider A, Hoyer H, Lotz B, et al. Screening for high-grade cervical intra-eplthelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int. J Cancer 2000;89: 529-534
16. International Agency of Research against Cancer Cervix cancer screening. IARC handbooks of cancer prevention. Lyon: IARC Press, 2005, vol. 10.